Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LDHA | P00338 | 1/20 | 0.36 |
| ▸ | SRR | Q9GZT4 | 1/20 | 0.36 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | ECE1 | P42892 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.30 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.30 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1259907 | 0.95 | LDHA (0.40) | LDHASRRSLC22A6TP53SMN1; SMN2 | |
| SCHEMBL7781837 | 0.95 | LDHA (0.40) | LDHASRRSLC22A6TP53SMN1; SMN2 | |
| 3-Hydroxybutyric Acid, (+/-)- SCHEMBL16915288 | 0.77 | LDHA (0.50) | LDHASRRSLC22A6TP53SMN1; SMN2 | |
| SCHEMBL17733 | 0.77 | ALDH1A1 (0.46) | LDHASRRSLC22A6MAPTALDH1A1 | |
| SCHEMBL11762118 | 0.76 | LDHA (0.47) | LDHASRRSLC22A6SMN1; SMN2MAPT | |
| SCHEMBL2775806 | 0.76 | CYP2C19 (0.44) | SLC22A6TP53ALDH1A1TDP1CYP2C19 | |
| SCHEMBL320091 | 0.76 | LDHA (0.61) | LDHASRRSLC22A6ALDH1A1LMNA | |
| SCHEMBL320485 | 0.76 | LDHA (0.61) | LDHASRRSLC22A6ALDH1A1LMNA | |
| SCHEMBL5665861 | 0.75 | ALDH1A1 (0.43) | TP53ALDH1A1TDP1CYP2C19 | |
| SCHEMBL28073104 | 0.75 | ALDH1A1 (0.43) | LDHASRRSLC22A6MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140329893-A1 | THERAPEUTIC COMPOSITIONS | BTG INTERNATIONAL LIMITED (GB) | 2014-11-06 | — | — | US | claimed |
| US-20120071548-A1 | Therapeutic compositions | BTG INTERNATIONAL LIMITED (GB) | 2012-03-22 | — | — | US | claimed |
| JP-4740426-B2 | — | — | 2011-08-03 | — | — | JP | claimed |
| US-20090253781-A1 | Therapeutic compositions | BTG INTERNATIONAL LIMITED (GB) | 2009-10-08 | — | — | US | claimed |
| EP-1017379-A4 | THERAPEUTIC COMPOSITIONS | BTG INT LTD (GB) | 2007-01-24 | — | — | EP | claimed |
| US-20040266872-A1 | Therapy of neuro-degenerative disorder by administering D-beta - hydroxybutyric acid, acetoacetate, or a metabolic precursor or physiologically acceptable salt of D- beta -hydroxybutyric acid or acetoacetate | BTG INTERNATIONAL LIMITED (GB) | 2004-12-30 | — | — | US | claimed |
| US-20030022937-A1 | Therapy of neuro-degenerative disorder by administering D-beta - hydroxybutyric acid, acetoacetate, or a metabolic precursor or physiologically acceptable salt of D- beta -hydroxybutyric acid or acetoacetate | BTG INTERNATIONAL LIMITED | 2003-01-30 | — | — | US | claimed |
| US-20010041736-A1 | Therapy for nervous system disorders | BTG INTERNATIONAL LIMITED | 2001-11-15 | — | — | US | claimed |
| EP-1017379-A1 | THERAPEUTIC COMPOSITIONS | BTG INTERNATIONAL LIMITED (GB) | 2000-07-12 | — | — | EP | claimed |
| CN-1256629-A | Therapeutic compositions | BRITISH TECH GROUP (GB) | 2000-06-14 | — | — | CN | claimed |
| WO-1998041201-A9 | THERAPEUTIC COMPOSITIONS | — | 1999-03-11 | — | — | WO | claimed |
| WO-1998041201-A1 | THERAPEUTIC COMPOSITIONS | BTG INTERNATIONAL LIMITED (GB) | 1998-09-24 | — | — | WO | claimed |
| WO-1998041200-A1 | THERAPEUTIC COMPOSITIONS | BTG INTERNATIONAL LIMITED (GB) | 1998-09-24 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071548-A1 | Therapeutic compositions | CPT1B, GYS1, IAPP | LDHA 116/4885SRR 2358/4885SLC22A6 1007/4885 |
| US-20010041736-A1 | Therapy for nervous system disorders | GYS1, CPT1B, PYGB | LDHA 141/4885SRR 1657/4885SLC22A6 654/4885 |
| US-20030022937-A1 | Therapy of neuro-degenerative disorder by administering D-beta - hydroxybutyric acid, acetoacetate, or a metabolic precursor or physiologically acceptable salt of D- beta -hydroxybutyric acid or acetoacetate | CPT1B, BDNF, IAPP | LDHA 207/4885SRR 2160/4885SLC22A6 550/4885 |
| US-20040266872-A1 | Therapy of neuro-degenerative disorder by administering D-beta - hydroxybutyric acid, acetoacetate, or a metabolic precursor or physiologically acceptable salt of D- beta -hydroxybutyric acid or acetoacetate | CPT1B, BDNF, IAPP | LDHA 207/4885SRR 2160/4885SLC22A6 550/4885 |
| US-20140329893-A1 | THERAPEUTIC COMPOSITIONS | CPT1B, GYS1, IAPP | LDHA 116/4885SRR 2358/4885SLC22A6 1007/4885 |
| US-20090253781-A1 | Therapeutic compositions | CPT1B, GYS1, IAPP | LDHA 116/4885SRR 2358/4885SLC22A6 1007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.